Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027

UNITED THERAPEUTICS Corp

District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.
Court expects to enter injunction barring FDA approval of Yutrepia until '793 patent expires May 14, 2027.
Court found Yutrepia would infringe '066 patent claims but held those claims invalid; United Therapeutics evaluating appeal.
PTAB recently invalidated '793 patent in IPR; United Therapeutics seeks rehearing and plans appeal; patent remains valid during appeals.
Both parties have right to appeal; United Therapeutics will vigorously defend IP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.